PharmaCyte Biotech Inc (PMCB)

[PINKribbon]

As with the name change from Nuvilex to PharmaCyte Biotech, so was there a change in the way of doing business. Outsourcing.

We know that PharmaCyte Biotech in its initial business state, was not structured and equipped in a way to conduct the science necessary to achieve their goals.

Fortunately, in his strategy to outsource the work, KW has not only been able to focus all his energy and resources on the success of (our) PC therapy development investment, but he’s also been saving the company tons of time and money in expenditures as well.

But of course, with the territory of outsourcing, it puts PharmaCyte/KW in the clutches of the contractors.

And therein lies KW’s vulnerabilities to shareholders hot buttons and patience. One most impacted is his inability to control time management as it seems to be frustrating to most here lately.

Patience. This development continues to be complex and time consuming.


Go Team PharmaCyte!!!